A University of Sydney patent details new cyclic peptides acting as coagulation factor XIa inhibitors reported to be useful for the treatment of thrombosis.
Acute inflammation is a physiological and host defense response to cardiac injury after suffering myocardial infarction (MI), which programmes cardiac repair and wound healing. Leukocyte-mediated innate inflammatory response is crucial to clear ischemic injury during MI; whilst macrophages produce specialized pro-resolving mediators such as maresin 1, the therapeutic potential of exogenous maresin 1 in cardiac repair is not clear.
Akari Therapeutics plc has unveiled a new pipeline candidate, AKTX-102, an antibody-drug conjugate (ADC) directed against CEACAM5, a novel target highly relevant in gastrointestinal and lung cancers.
Breast cancer is the most frequently diagnosed malignancy worldwide. Inhibiting PARP-mediated DNA repair has emerged as a promising anticancer strategy, with PARP inhibitors (PARPis) demonstrating clinical efficacy particularly in tumors with defective homologous recombination repair, such as BRCA-deficient cancers.
Starkage Therapeutics SAS has established a research collaboration with Gustave Roussy to characterize cellular senescence induced by standard-of-care treatments in a series of digestive cancers.
Programmed death-ligand 1 (PD-L1) is a crucial immune checkpoint ligand that inhibits antitumor immunity by engaging PD-1 on T cells, and checkpoint blockade has become a pillar of anticancer therapy. However, many patients show limited treatment responses.
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in this disease.
Mair Therapeutics BV has established a scientific collaboration with Radboud University to accelerate the discovery of small-molecule agonists of TMEM175, a lysosomal ion channel genetically linked to Parkinson’s disease.
Boehringer Ingelheim International GmbH and Simcere Pharmaceutical Group Ltd. have entered into a license and collaboration agreement to develop SIM-0709 for the treatment of inflammatory bowel disease.
Intratumoral regulatory T cells (Tregs) suppress antitumor immunity and are linked to poor prognosis across many cancers. These tumor-infiltrating Tregs express high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), making them attractive targets for immunotherapy. However, systemic Treg depletion carries the risk of severe autoimmune toxicity.
RSS
